LeMaitre Vascular, Inc.

LMAT

NASDAQ · Medical Devices

$80.89

At close - Nov 6, 4:00 PM EST - USD

Market Cap$1.85B

P/E29.5x

52W High$118.01

Volume326.44K

VCP Research Verdict2026Q3

Margin Strength Meets Decelerating Top-Line Momentum at LMAT

LeMaitre Vascular's gross margin of 71.7% in 2026Q3 remains well above the peer range, and free cash flow margin recovered to 28.9% from 12.8% in 2025Q1, suggesting the underlying franchise retains pricing power and cash generation.

Explore valuation models

MARKET ACTION

LMAT price & volume

Price trend, volume and key moving averages

Launch Terminal

Loading chart...

Market performance

Price History →

Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return

LMAT+1.83%

S&P 500 (^GSPC)+7.63%

1-Year Return

LMAT-4.39%

S&P 500 (^GSPC)+9.69%

3-Year Return

LMAT+69.04%

S&P 500 (^GSPC)+63.60%

5-Year Return

LMAT+54.05%

S&P 500 (^GSPC)+52.10%

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis

Trailing P/E5Y Low

29.5x

Forward P/EExpansion

28.5x

EV/EBITDA20th %ile

23.5x

FCF YieldCash Flow

3.6%

Valuation vs 5-Year History

Multiple Range

Metric

Current

5Y Median

Historical Range

Percentile

P/E

29.5x

42.4x

0th· Low

EV/EBITDA

23.5x

27.4x

20th· Low

Price/FCF

27.6x

43.2x

20th· Low

Current Multiple

5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection

Bear$36.03-55.5%

Base (Fair)$67.55-16.5%

Bull$92.14+13.9%

$36.03 Bear$67.55 Base$92.14 Bull

Current Market Price: $80.89

Trades at a 19.7% premium to Base DCF ($67.55)

Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend

Revenue FY25

$250M+13.5% YoY

Net income FY25

$58M+31.1% YoY

Free cash flow FY25

$74M+100.4% YoY

Operating margin FY25

27.2%+3.4 pts YoY

ROIC (FY25)9.7%

Avg ROIC 5Y9.8%

ROE (TTM)15.3%

Piotroski Score7 / 9

Financial Statements →

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History

EPS Beat Rate8/12 (67%)

Revenue Beat Rate6/12 (50%)

Quarter	EPS (Act vs Est)	Revenue (Act vs Est)
Q4 2026Latest Nov 4, 2026	$0.65-5.2% vs $0.69	$68M+0.9% vs $67M
Q3 2026 Aug 4, 2026	$0.74-8.3% vs $0.81	$70M-1.5% vs $71M
Q2 2026 May 5, 2026	$0.68+3.0% vs $0.66	$67M-0.2% vs $67M
Q1 2026 Feb 25, 2026	$0.68+1.5% vs $0.67	$64M+2.6% vs $63M

Historical baseline: 12 quarters analyzedGAAP / Adjusted

MARKET COVERAGE

Latest News

4 Stories

Seeking Alpha·22h ago

LeMaitre Vascular, Inc. (LMAT) Q3 2026 Earnings Call Transcript

LeMaitre Vascular, Inc. ( LMAT ) Q3 2026 Earnings Call November 4, 2026 5:00 PM EST Company Participants Dorian LeBlanc - Chief Financial Officer George LeMaitre - Chairman & CEO Conference Call Participants Michael Petusky - Barrington Research Associates, Inc., Research Division Nathan Treybeck - Wells Fargo Securities, LLC, Research Division Brett Fishbin - KeyBanc Capital Markets Inc., Research Division Daniel Stauder - Citizens JMP Securities, LLC, Research Division James Sidoti - Sidoti & Company, LLC Michael Sarcone - Jefferies LLC, Research Division Presentation Operator Welcome to the LeMaitre Vascular Q3 2026 financial results conference call. As a reminder, today's call is being recorded.

GlobeNewsWire·1d ago

LeMaitre to Participate in Upcoming Investor Conferences

BURLINGTON, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in three upcoming investor conferences.

MarketBeat·3d ago

LeMaitre Vascular Q3 Earnings Call Highlights

LeMaitre Vascular NASDAQ: LMAT reported 12% organic sales growth in the third quarter of 2026, driven by higher prices and unit volumes, while reiterating its full-year organic growth outlook and lowering its gross margin forecast.

Zacks Investment Research·3d ago

LeMaitre Vascular (LMAT) Misses Q3 Earnings Estimates

LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.65 per share, missing the Zacks Consensus Estimate of $0.69 per share. This compares to earnings of $0.62 per share a year ago.

Filtered for LeMaitre Vascular, Inc.More Headlines

Compare before deciding

Benchmark LMAT against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for LeMaitre Vascular, Inc. (LMAT)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
LMATLeMaitre Vascular, Inc.Current	$80.89	$1.85B	29.47	13.53%	23.51%	15.33%	0.98%
ATRCAtriCure, Inc.	$58.54	$2.98B	195.98	14.88%	2.52%	2.93%	—
NVCRNovocure Ltd	$13.28	$1.54B	-12.74	8.28%	-16.78%	-35.81%	—
ANGOAngioDynamics, Inc.	$11.73	$484.83M	-14.97	9.46%	-10.12%	-19.25%	—
CNMDCONMED Corporation	$51.50	$1.54B	21.13	5.16%	5.36%	7.07%	1.54%
MMSIMerit Medical Systems, Inc.	$87.23	$5.2B	32.89	11.66%	9.94%	9.65%	—

Compare LMAT vs Peers

LeMaitre Vascular, Inc. (LMAT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ATRC

Most directly comparable listed peer for LMAT.

Scale Benchmark

vs ABT

Larger-name benchmark to compare LMAT against a more recognizable public peer.

Peer Set

Compare Top 5

vs ATRC, NVCR, ANGO, CNMD

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

LMAT SEC Filings & Documents

LeMaitre Vascular, Inc. (LMAT) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Nov 4, 2026·SEC

Material company update

Oct 15, 2026·SEC

Material company update

Aug 4, 2026·SEC

10-K Annual Reports

FY 2026

Feb 26, 2026·SEC

FY 2025

Feb 28, 2025·SEC

10-Q Quarterly Reports

FY 2026

Nov 5, 2026·SEC

FY 2026

Aug 5, 2026·SEC

FY 2026

May 6, 2026·SEC

Get notified when LMAT posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

LMAT Frequently Asked Questions

LeMaitre Vascular, Inc. (LMAT) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is LeMaitre Vascular, Inc.'s revenue?

LeMaitre Vascular, Inc. (LMAT) reported $269.4M in revenue over the trailing twelve months. Revenue was $249.6M in fiscal year 2025. That is 853% more than the $26.2M of fiscal year 2004.

How fast is LeMaitre Vascular, Inc. growing?

LeMaitre Vascular, Inc. (LMAT) grew revenue by 11.8% over the trailing twelve months, compared with the twelve months before.

Is LMAT profitable?

Yes. LeMaitre Vascular, Inc. (LMAT) earned $63.3M in net income over the trailing twelve months (a 23.5% net margin).

Dividend & Returns

Does LMAT pay dividends?

Yes. LeMaitre Vascular, Inc. (LMAT) pays a dividend that yields 0.98% at the current price, a small yield.

What is LMAT's return on equity?

LeMaitre Vascular, Inc. (LMAT) had a return on equity (ROE) of 15.3% over the trailing twelve months. That is above the market's typical 10-15%.

What is LeMaitre Vascular, Inc.'s free cash flow?

LeMaitre Vascular, Inc. (LMAT) generated $67.0M in free cash flow over the trailing twelve months.

What if you invested $1,000 in LMAT back in 2004?

Total return calculator · dividends reinvested · 22+ years of data

See returns →

Quarter

EPS (Act vs Est)

Revenue (Act vs Est)

Q4 2026Latest

Nov 4, 2026

$0.65-5.2%

vs $0.69

$68M+0.9%

vs $67M

Q3 2026

Aug 4, 2026

$0.74-8.3%

vs $0.81

$70M-1.5%

vs $71M

Q2 2026

May 5, 2026

$0.68+3.0%

vs $0.66

$67M-0.2%

vs $67M

Q1 2026

Feb 25, 2026

$0.68+1.5%

vs $0.67

$64M+2.6%

vs $63M

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

LMATLeMaitre Vascular, Inc.Current

$80.89

$1.85B

29.47

13.53%

23.51%

15.33%

0.98%

ATRCAtriCure, Inc.

$58.54

$2.98B

195.98

14.88%

2.52%

2.93%

—

NVCRNovocure Ltd

$13.28

$1.54B

-12.74

8.28%

-16.78%

-35.81%

—

ANGOAngioDynamics, Inc.

$11.73

$484.83M

-14.97

9.46%

-10.12%

-19.25%

—

CNMDCONMED Corporation

$51.50

$1.54B

21.13

5.16%

5.36%

7.07%

1.54%

MMSIMerit Medical Systems, Inc.

$87.23

$5.2B

32.89

11.66%

9.94%

9.65%

—